| ²é¿´: 669 | »Ø¸´: 1 | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
xing2007½ð³æ (³õÈëÎÄ̳)
|
[½»Á÷]
Ó¢·ÖÐ-·ÖÀëÌáÈ¡
|
||
|
Because of a tendency toward increased nitrogen concentration in the last three aqueous residues of Fraction VIII, these were kept separate. The remaining 1.74 gm. of this most water-soluble material were crystallized from chloroform and yielded 0.150 gm. of crystalline material. Fractions IV and V were likewise crystallized from chloroform and yielded respectively 0.375 and 0.508 gm. of crystals. These crystalline deposits from chloroform were combined with Fraction III, since according to solubility, melting point, specific rotation, and bioassay they were very similar, as can be seen from Table I. The assay of these fractions by the work test indicates that they are a mixture of 11-dehydro-17-hydroxycorticosterone and 17-hydroxycorticosterone, since assay values between those for these two compounds were obtained. These substances were obtained in pure form by following the specific rotation in 95 per cent alcohol. Melting point determinations are of no value as a criterion for separation, since they are practically identical and show little if any depression when the compounds are mixed. The specific rotations of pure samples of these compounds previously isolated were found to be 164¡ã for 17-hydroxycorticosterone and 195¡ã for ll-dehydro-17-hydroxycorticosterone. These values are in agreement with those reported in the literature . By fractional crystallization from acetone it was found that the material least soluble in this solvent could be obtained in pure form, since on repeated crystallization no difference in specific rotation could be effected. 1.2 gm. of this substance were obtained, which, as is evident from the data in Table I, is undoubtedly 17-hydroxycorticosterone. A mixed melting point with a pure sample of this compound previously obtained gave no depression. |
» ²ÂÄãϲ»¶
¿¼Ñе÷¼Á
ÒѾÓÐ15È˻ظ´
Ò»Ö¾Ô¸2110£¬»¯Ñ§Ñ§Ë¶310·Ö£¬±¾¿ÆÖصãË«·ÇÇóµ÷¼Á
ÒѾÓÐ17È˻ظ´
282£¬Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
»¯Ñ§¹¤³Ìµ÷¼Á289
ÒѾÓÐ47È˻ظ´
297Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
»úеר˶270Çóµ÷¼Á£¬½ÓÊÜ¿çרҵ
ÒѾÓÐ4È˻ظ´
»¹Óл¯¹¤¶þÂÖµ÷¼ÁµÄѧУÂð
ÒѾÓÐ37È˻ظ´
22408µ÷¼ÁÇóÖú
ÒѾÓÐ5È˻ظ´
»¯¹¤µ÷¼ÁÇóµ¼Ê¦ÊÕÁô£¡Ò»Ö¾Ô¸Ê§Àû£¬Ì¤Êµ¿Ï¸É£¬ÓÐÖ²ÎïÌáÈ¡¿ÆÑоÀú
ÒѾÓÐ7È˻ظ´
²ÄÁϹ¤³Ì302·ÖÇóµ÷¼Á
ÒѾÓÐ14È˻ظ´
hekai16
ľ³æ (ÕýʽдÊÖ)
- ·ÒëEPI: 9
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 5655.5
- É¢½ð: 230
- ºì»¨: 2
- Ìû×Ó: 472
- ÔÚÏß: 8611.6Сʱ
- ³æºÅ: 848484
- ×¢²á: 2009-09-15
- רҵ: ÉúÎï´ó·Ö×ӽṹÓ빦ÄÜ
xing2007(½ð±Ò+10, ·ÒëEPI+1): 2010-08-02 07:35:44
| ÓÉÓÚ×é·ÖÈýÖеÄ×îºó3¸öË®Ïà½þÌáÎïµÄº¬µª³É·ÖÓÐÔö¸ßµÄÇ÷ÊÆ£¬¹Ê½«ËûÃÇ·Ö¿ª±£´æ¡£½«Ê£ÏµÄ1.74¿ËµÄË®ÈÜÐԽϴóÎïÖÊÓÃÈýÂȼ×Íé½á¾§£¬µÃµ½0.15¿Ë½á¾§¡£×é·ÖËĺÍÎåÓÃͬÑùµÄ·½·¨ÓÃÈýÂȼ×Íé½á¾§£¬·Ö±ðµÃµ½0375ºÍ0.508¿Ë¾§Ìå¡£ÕâЩÓÃÈýÂȼ×Íé½á¾§µÃµ½µÄ¾§ÌåÓÉÓÚÆäË®ÈÜÐÔ£¬È۵㡢Ðý¹âÐÔºÍÉúÎïÐÔÖÊÓë×é·ÖÈýºÜÏàËÆ£¨¼û±íÒ»£©£¬½«ËûÃǺϲ¢¡£Í¨¹ý¶ÔÕâЩ×é·ÖµÄ·ÖÎö£¬¿ÉÖªËüÃÇÊÇ11-dehydro-17-hydroxycorticosterone ºÍ17-hydroxycorticosterone µÄ»ìºÏÎï¡£ÓÉ´Ë¿ÉÖªÕâÁ½ÖÖ»¯ºÏÎïÖÐÕâЩ³É·ÖµÄÐÔÖÊ¡£¸ú×ÙÕâЩÎïÖÊÔÚ95%ÒÒ´¼ÖеıÈÐýÂÉÎÒÃǵõ½Á˸ߴ¿¶ÈµÄµ¥Ìå¡£½«£¨ÕâЩ£©ÎïÖʵÄÈÛµã×÷Ϊ·ÖÀë µÄ±ê׼ûÓÐÈκÎÒâÒ壬ÒòΪËûÃǼ¸ºõÏàͬÇÒ»ìºÏʱûÓлòÕßÖ»ÓÐÒ»µã²îÒì¡£ ´¿ÑùÆ·ÖÐ17-hydroxycorticosterone ºÍ ll-dehydro-17-hydroxycorticosteroneµÄ±ÈÐý¶È·Ö±ðΪ164ºÍ195£¬ÕâЩÊýÖµÓëÎÄÏ×ÖеÄÎǺϡ£Í¨¹ýÓñûÍªÖØ½á¾§£¬ÎÒÃÇ·¢ÏÖ¸ÃÎïÖÊÔÚ±ûͪÖеÄÈܽâ¶ÈºÜС£¬µÄµ½µÄ¾§ÌåºÜ´¿¡£ÓÉÓÚÖØ¸´½á¾§¶Ô¸ÃÎïÖʵıÈÐý¶ÈûÓÐÓ°Ï죬ÎÒÃǵõ½ÁË1.2¿Ë17-hydroxycorticosteroneµ¥Ì壨Êý¾Ý¼û±íÒ»£©£¬½«ÆäÓëÏÈǰµÃµ½µÄ±ê×¼Îï»ìºÏºó»ìºÏÎïµÄÈ۵㲻±ä¡£ |
2Â¥2010-08-01 14:13:26













»Ø¸´´ËÂ¥